TB Alliance and GSK announce partnership to develop new TB therapeutics
NEW YORK (March 18, 2021)—TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that […]
R&D News
ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
WALTHAM, Mass., February 1, 2021 – ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
Guilford, Conn., June 2, 2020, InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning
TB Alliance Partners with ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments against Tuberculosis
NEW YORK (January 29, 2020)—TB Alliance and partners announced the launch of the ERA4TB (European Regimen Accelerator for Tuberculosis) project
New Research Assesses Efficacy of Different Doses of Linezolid, Key Medicine Used in Regimens that Treat Drug-Resistant Tuberculosis
NEW YORK (January 27, 2020)—New peer-reviewed research has evaluated the efficacy of different doses and schedules of linezolid for the treatment
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.